Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine
In present study the immediate and long-term therapy results of 14 patients with refractory chronic lymphocytic leukemia (CLL) are analyzed. Treatment program included alemtuzumab alone or in combination with fludarabine.
Saved in:
Main Authors: | E. V. Kataeva, A. K. Golenkov, E. V. Trifonova, G. A. Dudina, T. A. Mitina, L. L. Vysotskaya, T. D. Lutskaya, I. V. Buravtsova, R. V. Gorenkov, Yu. Yu. Chuksina, V. V. Yazdovskiy |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2014-07-01
|
Series: | Онкогематология |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/95 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Alemtuzumab in treatment of chronic lymphocytic leukemia
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01) -
IMMUNE AND CYTOKINE STATUS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING ALEMTUZUMAB
by: M. N Khorobrykh, et al.
Published: (2014-07-01) -
First research of use Vero-Fludarabine in chronic lymphocytic leukemia and non-hodgkins lymphoma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01) -
Retrospective, multi-centre, open-label study on the use of alemtuzumab for relapsing–remitting multiple sclerosis in clinical practice: A 4-year follow-up
by: A. Pato-Pato, et al.
Published: (2025-07-01) -
Initial renal function and type of chemotherapy: impact on treatment efficacy in patients with chronic lymphocytic leukemia
by: A. K. Nikitina, et al.
Published: (2015-06-01)